TELA Bio (TELA) reported a Q4 net loss Thursday of $0.23 per diluted share, compared to a loss of $0.53 a year earlier.
One analyst polled by FactSet expected a loss of $0.24.
Revenue for the quarter ended Dec. 31 was $17.6 million, up from $17 million a year earlier.
Analysts polled by FactSet expected $23.2 million.
For Q1, the company has a revenue outlook of $17 million to $18 million. Four analysts expect $21 million.
The company expects full-year 2025 revenue between $85 million to $88 million. Analysts expect $93.8 million.
Shares fell 24% in recent after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。